BioXcel Therapeutics Inc expected to post a loss of 91 cents a share - Earnings Preview

BioXcel Therapeutics

08/03/2024 12:50

* BioXcel Therapeutics Inc  BTAI.OQ   BTAI.O  is expected
to show
a rise in quarterly revenue when it reports  results on March 12
for the period ending December 31 2023
    * The New Haven Connecticut-based  company is expected to
report a
198.8% increase in revenue to $711.13 thousand from $238
thousand a year ago, according to the mean estimate from 8
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for BioXcel Therapeutics Inc
is
for a loss of 91 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for BioXcel
Therapeutics Inc is $11.50​, above​ its last closing price
of $3.04. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -1.34       -1.30      -1.72     Missed  -31.9
 Jun. 30 2023  -1.80       -1.75      -1.83     Missed  -4.5
 Mar. 31 2023  -1.81       -1.62      -1.84     Missed  -13.7​
 Dec. 31 2022  -1.49       -1.45      -1.95     Missed  -34.8
 ​​Sep.        -1.33       -1.35      -1.49     Missed  -10.5
 30 2022                                                
 Jun. 30 2022  -1.23       -1.22      -1.35     Missed  -10.7​
 Mar. 31 2022  -1.11       -1.15      -1.12     Beat    2.3
 Dec. 31 2021  -1.14       -1.10      -0.93     Beat    15.8
 This summary was machine generated March 8 at 12:49 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)